EGFR gene mutation+1
RecruitingStudy on Patritumab Deruxtecan and Zirconium (89Zr) Patritumab Deruxtecan for Patients with Advanced EGFR Mutation Positive Lung Cancer
Study on Patritumab Deruxtecan and Zirconium (89Zr) Patritumab Deruxtecan for Patients with Advanced EGFR Mutation Positive Lung Cancer
- Disease:EGFR gene mutationLung neoplasm malignant
- Substances:89Zr-U3-1402Patritumab Deruxtecan
The Netherlands- Participants:18–64 years · 65+ years
- Substances:89Zr-U3-1402
- Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting








